Data from: Vasohibin1, a new IRES trans-acting factor for induction of (lymph)angiogenic factors in early hypoxia

Hantelys, Fransky; Godet, Anne-Claire; David, Florian; Tatin, Florence; Renaud-Gabardos, Edith; Pujol, Francoise; Diallo, Leila; ADER, Isabelle; Ligat, Laetitia; Henras, Anthony; Sato, Yasufumi; Parini, Angelo; Lacazette, Eric; Garmy-Susini, Barbara; Prats, Anne-Catherine

doi:10.5061/dryad.2330r1b

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Preprint1

Other1

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Vasohibin1, a new IRES trans-acting factor for induction of (lymph)angiogenic factors in early hypoxia

Hantelys

Godet

David

et al. 2018

Preprint

Self Cite

View full text Add to dashboard Cite

Hypoxia, a major inducer of angiogenesis, is known to trigger major changes of gene expression at the transcriptional level. Furthermore, global protein synthesis is blocked while internal ribosome entry sites (IRES) allow specific mRNAs to be translated. Here we report the transcriptome and translatome signatures of (lymph)angiogenic genes in hypoxic HL-1 cardiomyocytes: most genes are not induced at the transcriptome-, but at the translatome level, including all IRES-containing mRNAs. Our data reveal sequential activation of (lymph)angiogenic mRNA IRESs in early hypoxia. We identify vasohibin1 (VASH1) as an IRES trans-acting factor (ITAF) able to activate the earliest induced FGF1 IRES while it inhibits the other IRESs. Thus this new ITAF may have opposite effects on IRES activities in the steps of early hypoxia. These data suggest that IRESome composition varies at different stages of hypoxia, leading to sequential induction of (lymph)angiogenic factors required to form new functional vessels in ischemic heart.

show abstract